Research programme: lung disease therapeutics - PharmaMax

Drug Profile

Research programme: lung disease therapeutics - PharmaMax

Alternative Names: RES-001; RES-100; RES-110; RES-200; RES-300; RES-600; RES-800; RES-900

Latest Information Update: 22 Jan 2016

Price : $50

At a glance

  • Originator PharmaMax
  • Class
  • Mechanism of Action Beta-adrenergic receptor agonists; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Cough; Lung cancer; Pulmonary fibrosis

Most Recent Events

  • 22 Jan 2016 Preclinical trials in Chronic obstructive pulmonary disease in China (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top